Drug Profile

SMT 738

Alternative Names: DDS-04 series; Eskape pathogen programme - Summit Therapeutics; SMT-026738; SMT-738

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Summit Therapeutics
Class Antibacterials; Small molecules
Mechanism of Action ATP-binding cassette transporter modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Enterobacteriaceae infections

Most Recent Events

20 Feb 2024 Discontinued - Preclinical for Enterobacteriaceae-infections in USA (IV) prior to February 2024
28 Mar 2023 SMT 738 is available for licensing as of 31 Dec 2022. https://www.smmttx.com/our-company/strategy-mission/
31 Dec 2022 Summit Therapeutics has patent pending for SMT 738 directed to the composition of matter program in the world

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com